Prescription Patterns, Resource Utilization & Costs - Add-on Therapy With Anti Dipeptidyl Peptidase-IVs vs Rosiglitazone
Completed
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Registration Number
- NCT01332370
- Lead Sponsor
- GlaxoSmithKline
- Brief Summary
This retrospective database study analyzed resource utilization and costs associated with sitagliptin (STG) in comparison with rosiglitazone (RSG) added to metformin (MET) monotherapy among adults with a diagnosis of diabetes who were continuously enrolled in a large US healthcare plan.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 5391
Inclusion Criteria
- Continuously enrolled in the health insurance plan to ensure complete claims coverage
- At least 1 claim with a diagnosis of diabetes (ICD-9 250.xx)
- Aged 18 years or older at the index date
- At least 6 months of baseline period prior to the index date
- At least 1 claim for MET during the baseline period
- At least 180 days of continuous therapy with RSG+MET or STG+MET after the index date
Exclusion Criteria
- At least 1 claim for insulin or sulfonylurea in the baseline period
- At least 1 claim with a diagnosis of congestive heart failure in the baseline period
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Adults with Type 2 Diabetes Sitagliptin + Metformin Subjects with a diagnosis (ICD-9 code) of diabetes Adults with Type 2 Diabetes Rosiglitazone + Metformin Subjects with a diagnosis (ICD-9 code) of diabetes
- Primary Outcome Measures
Name Time Method medical resource utilization at least 12 months following first prescription with RSG or STG as an add-on therapy to MET monotherapy. Direct healthcare and indirect sick leave costs
- Secondary Outcome Measures
Name Time Method